• 1
    Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J. Urol. 1993; 150: 54651.
  • 2
    Nasu K, Moriyama N, Kawabe K et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br. J. Pharmacol. 1996; 119: 797803.
  • 3
    Smith MS, Schambra UB, Wilson KH, Page SO, Schwinn DA. Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha 1-adrenergic receptor subtypes at four distinct levels. Brain Res. Mol. Brain Res. 1999; 63: 25461.
  • 4
    Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J. Urol. 2002; 167: 17783.
  • 5
    Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62: 13567.
  • 6
    Wilt TJ, MacDonald R, Rutks I. Tamsulosin for benign prostatic hyperplasia (Cochrane Review). Cochrane Database Syst. Rev. 2003: CD002081.
  • 7
    Mebust WK, Bosch R, Donovan J et al. Symptom evaluation, quality of life and sexuality. In: CockettAT, KhouryS, AsoY et al. (eds). Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH); 27–30 June 1993. Paris, France, 1993: 12947.
  • 8
    Arai Y, Aoki Y, Okubo K et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J. Urol. 2000; 164: 120611.
  • 9
    Arai Y, Okubo K, Okada T, Maekawa S, Aoki Y, Maeda H. Interstitial laser coagulation for management of benign prostatic hyperplasia: a Japanese experience. J. Urol. 1998; 159: 19615.
  • 10
    Terada N, Aoki Y, Ichioka K et al. Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: response durability and variables potentially predicting response. Urology 2001; 57: 701705.
  • 11
    Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892900.
  • 12
    Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: 901906.
  • 13
    Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 46670.
  • 14
    Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19 365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J. Urol. 1998; 160: 78491.
  • 15
    Schulman CC, Cortvriend J, Jonas U, Lock TMTW, Vaage S, Speakman MJ. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur. Urol. 1996; 29: 14554.
  • 16
    Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur. Urol. 1999; 36: 60920.
  • 17
    Schulman CC, Lock TM, Buzelin JM et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J. Urol. 2001; 166: 135863.
  • 18
    Rossi C, Kortmann BB, Sonke GS et al. α-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J. Urol. 2001; 165: 3841.
  • 19
    Arnold EP. Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand. BJU Int. 2001; 87: 2430.
  • 20
    Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J. Urol. 2002; 167: 17349.